If your diagnosis sounds like a sentence full of extra words — "astrocytoma, IDH-mutant, grade 3" — there is a reason. In 2021, the World Health Organization released a major update to how brain tumors are classified, and it changed the names patients see on their pathology reports.
For most of medical history, brain tumors were classified by how they looked under a microscope. A pathologist examined the tissue and judged the cell type and grade by appearance. That approach was useful but imperfect: tumors that looked similar sometimes behaved very differently.
The 2021 classification (often called WHO CNS5) integrated molecular markers — specific gene and chromosome changes inside the tumor — directly into the diagnosis. The result is a system where many gliomas are now defined by their biology, not just their appearance.
For adult diffuse gliomas, this simplified a once-confusing list into three core types:
- Astrocytoma, IDH-mutant (graded 2, 3, or 4)
- Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (graded 2 or 3)
- Glioblastoma, IDH-wildtype (grade 4)
The classification also recognized that children's gliomas are biologically distinct from adults' and gave them their own categories, and it switched grade numbers from Roman to Arabic numerals (so you'll see "grade 4," not "grade IV").
Why does this matter to you? Because molecular markers predict behavior and guide treatment more reliably than appearance alone. The same markers that define your tumor's name also help your team estimate prognosis, choose therapy, and, increasingly, match you to targeted drugs. When you see those extra words on your report, they are not bureaucratic clutter — they are the most precise description medicine can currently give of your specific tumor.